Arabidopsis heat shock transcription factor HSFA7b positively mediates salt stress tolerance by binding to an E-box-like motif to regulate gene expression

por Zang, Dandan, Wang, Jingxin, Zhang, Xin, Liu, Zhujun, Wang, Yucheng
Publicado 2019

Hesperidin Inhibits Lung Cancer In Vitro and In Vivo Through PinX1

por Yao, Yang, Lin, Mingyue, Liu, Zhujun, Liu, Mengyang, Zhang, Shiheng, Zhang, Yukun
Publicado 2022

Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics

por Yang, Dengxia, Woodard, Gavitt, Zhou, Chan, Wang, Xinyue, Liu, Zhujun, Ye, Zhaoxiang, Li, Kai
Publicado 2016

Tumor necrosis factor superfamily 15 promotes lymphatic metastasis via upregulation of vascular endothelial growth factor‐C in a mouse model of lung cancer

por Qin, Tingting, Huang, Dingzhi, Liu, Zhujun, Zhang, Xiaoling, Jia, Yanan, Xian, Cory J., Li, Kai
Publicado 2018

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

por Liu, Shaochuan, Qin, Tingting, Liu, Zhujun, Wang, Jing, Jia, Yanan, Feng, Yingfang, Gao, Yuan, Li, Kai
Publicado 2020

Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling

por Qin, Tingting, Liu, Zhujun, Wang, Jing, Xia, Junling, Liu, Shaochuan, Jia, Yanan, Liu, Hailin, Li, Kai
Publicado 2020

Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling

por Zhang, Xiaoling, Zhang, Yan, Jia, Yanan, Qin, Tingting, Zhang, Cuicui, Li, Yueya, Huang, Chengmou, Liu, Zhujun, Wang, Jing, Li, Kai
Publicado 2020

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab

por Liu, Zhujun, Qin, Tingting, Yuan, Xiaohan, Yang, Jie, Shi, Wei, Zhang, Xiaoling, Jia, Yanan, Liu, Shaochuan, Wang, Jing, Li, Kai
Publicado 2022

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study

por Liu, Zhujun, Wang, Jing, Meng, Zhaoting, Wang, Xinyue, Zhang, Cuicui, Qin, Tingting, Chen, Jinliang, Jiang, Xiangli, Wang, Liuchun, Lin, Li, Zhang, Xiaoling, Chen, Peng, Huang, Chun, Jiang, Richeng, Li, Kai
Publicado 2018

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospecti...

por Zhang, Linlin, Wang, Liuchun, Wang, Jingya, Chen, Jinliang, Meng, Zhaoting, Liu, Zhujun, Jiang, Xiangli, Wang, Xinyue, Huang, Chun, Chen, Peng, Liang, Yan, Jiang, Richeng, Wang, Jing, Zhong, Diansheng, Shang, Yanhong, Zhang, Yan, Zhang, Cuiying, Huang, Dingzhi
Publicado 2023

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

por Wang, Jing, Zhao, Yizhuo, Wang, Qiming, Zhang, Li, Shi, Jianhua, Wang, Zhehai, Cheng, Ying, He, Jianxing, Shi, Yuankai, Yu, Hao, Zhao, Yang, Chen, Weiqiang, Luo, Yi, Wang, Xiuwen, Nan, Kejun, Jin, Faguang, Dong, Jian, Li, Baolan, Liu, Zhujun, Han, Baohui, Li, Kai
Publicado 2018